Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to compare progression‐free survival in transplant‐ineligible newly diagnosed multiple myeloma patients treated with Daratumumab‐lenalidomide‐dexamethasone in the MAIA trial and similar patients treated with VRd or Vd in routine clinical practice settings

X
Trial Profile

A study to compare progression‐free survival in transplant‐ineligible newly diagnosed multiple myeloma patients treated with Daratumumab‐lenalidomide‐dexamethasone in the MAIA trial and similar patients treated with VRd or Vd in routine clinical practice settings

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PEGASUS
  • Most Recent Events

    • 18 Dec 2020 New trial record
    • 01 Dec 2020 Results published in the American Journal of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top